triple-combination therapy – Don't Forget To Breathe

GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol significantly reduced the amount of exacerbations experienced by patients with chronic obstructive pulmonary disease compared with AstraZeneca’s Symbicort Turbohaler, according to phase 3 study results presented at the 2016 European Respiratory Society International Congress. Results showed that patients in the triple-combination therapy group hadContinue reading “Triple-combination therapy reduces COPD exacerbations”